Gastroenteropancreatic Neuroendocrine Carcinoma

• CLINICAL_TRIALS research · 2026-04-08
  Clinical Trial Update: Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors [Phase 1, Phase 2]

  A Phase 1/2 clinical trial of the DLL3-targeting radiopharmaceutical [212Pb]Pb-DOTAM-MAM279 (MP0712) in small cell lung cancer and other DLL…

• CLINICAL_TRIALS research · 2026-03-24
  Clinical Trial Update: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors [Phase 1]

  Phase I study of [225Ac]Ac-ETN029 for DLL3-expressing advanced solid tumors is currently recruiting, sponsored by Novartis Pharmaceuticals.

• CLINICAL_TRIALS research · 2026-02-11
  Clinical Trial Update: Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) [Phase 3]

  Phase 3 trial evaluating tarlatamab vs standard-of-care chemotherapy in pre-treated advanced pulmonary or gastroenteropancreatic poorly diff…

• CLINICAL_TRIALS research · 2026-02-09
  Clinical Trial Update: Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors [Phase 1]

  Phase 1 clinical trial update on the investigational agent BL-M14D1 for locally advanced or metastatic small cell lung cancer and a range of…

• CLINICAL_TRIALS research · 2025-09-23
  Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]

  Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2025-04-01
  Clinical Trial Update: Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) [Phase 2]

  Phase 2 trial evaluating nivolumab with or without ipilimumab in patients with advanced, refractory pulmonary or gastroenteropancreatic poor…

• CLINICAL_TRIALS trial_result · 2019-12-30
  Clinical Trial Update: Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes [Phase 2]

  Phase II study of avelumab as second-line treatment for metastatic gastroenteropancreatic neuroendocrine carcinoma (WHO Grade 3) afteretopos…

• CLINICAL_TRIALS trial_result · 2019-12-19
  Clinical Trial Update: Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) [Phase 2]

  Phase 2 trial investigating everolimus with temozolomide in advanced gastroenteropancreatic neuroendocrine carcinoma (G3) has completed.